Results 211 to 220 of about 28,920 (253)

Antifungal Susceptibility Testing in Teaching Hospitals

Annals of Pharmacotherapy, 2003
BACKGROUND: An assessment of antifungal susceptibility testing (AST) has not been conducted since the introduction of the National Committee for Clinical Laboratory Standards (NCCLS) M27-A document. OBJECTIVE: To determine AST ...
Manjunath P, Pai, Susan L, Pendland
openaire   +2 more sources

Antifungal Susceptibility Testing Methods

Current Drug Targets, 2005
The number of systemically active antifungal agents has increased dramatically in recent years in response to the challenge of invasive mycoses. Additional work is needed to better understand the mechanisms of action of these agents as well as the mechanisms of resistance expressed by the fungal pathogens.
openaire   +2 more sources

Antifungal Agents and Antifungal Susceptibility Testing

2010
1 Systemic Antifungal Drugs in Current Use 2 Future Antifungal Drugs 3 Antifungal Susceptibility Testing 4 Methods of Susceptibility Testing Keywords: antifungal agents and antifungal susceptibility testing; systemic antifungal drugs in current use; antifungal mechanisms of action; lipid vehicles for polyenes; unique ...
Sanjay G. Revankar, John R. Graybill, Thomas F. Patterson   +2 more
openaire   +1 more source

Antifungal Drug Susceptibility Testing

1989
The continuing introduction of new antifungal drugs has increased the demand for methods of in vitro testing that can predict the effects of compounds in vivo. As with antibacterial drugs, tests designed to ascertain the minimum amount of drug needed to inhibit the growth of organisms in vitro (minimum inhibitory concentration, or MIC) have often been ...
openaire   +2 more sources

Antifungal Susceptibility Testing: A Primer for Clinicians

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2012
Antifungal susceptibility testing is not as commonly performed as antibacterial susceptibility testing. The methodology for detecting antifungal resistance is newer and requires different testing supplies that may not be readily available in a clinical laboratory setting. Breakpoints for molds are lacking.
Kristi M, Kuper, Elizabeth A, Coyle, Audrey, Wanger   +2 more
openaire   +2 more sources

Antifungal drug susceptibility testing

Mycopathologia, 1984
The advent of new antifungal drugs provides clinicians with therapeutic options, and it is anticipated requests for fungal susceptibility testing in vitro will increase. Our own laboratory's experience indicates that results can be provided promptly even to distant medical centers.
openaire   +2 more sources

Antifungal susceptibility testing with dermatophytes

Mycoses, 1991
Summary. The determination of the in vitro activity of antimycotics against dermatophytes has for long been considered as irrelevant from a practical point of view. Recently, however, this approach has been questioned. Various different tests such as agar diffusion test, agar dilution test and broth dilution test can be used for the determination of ...
Aletta Georgii, H. C. Korting
openaire   +1 more source

Progress in Standardizing Antifungal Susceptibility Tests

Clinics in Laboratory Medicine, 1989
In vitro tests of antifungal agents are receiving increasing attention as important procedures for the clinical laboratory. As antifungal agents proliferate, it will become more and more valuable to have available antifungal susceptibility tests to aid in treatment selections based on the specific activities of different drugs against a patient's own ...
openaire   +2 more sources

Etest for antifungal susceptibility testing of yeasts

Diagnostic Microbiology and Infectious Disease, 1994
Comparison [+/- 1 dilution between minimum inhibitory concentrations (MICs)] of fluconazole and flucytosine Etest MICs of 10 candidate quality control yeast isolates and 78 clinical isolates demonstrated good agreement (> or = 90%) with the reference method (National Committee for Clinical Laboratory Standards document M27-P).
openaire   +2 more sources

Antifungal Susceptibility Testing and Therapy

2009
The development of new therapies to treat fatal diseases is creating an increasing number of patients who have predisposing factors for infections by opportunistic yeasts. The rise in the prevalence of fungal infections has been the drive to develop and license several new antifungal agents such as new formulations of polyenes, new triazole agents and ...
Manuel Cuenca-Estrella, Juan Luis Rodriguez-Tudela   +1 more
openaire   +1 more source